This is an amendment to 16.19.20 NMAC, Sections 65, 68 and 69, effective 9/14/2021.

16.19.20.65 SCHEDULE I:

A. Section 30-31-6 NMSA 1978, schedule I shall consist of the following drugs and other substances, by whatever name, common or usual name, chemical name or brand name designated, listed in this section; **OPIOIDS**, unless specifically exempt or unless listed in another schedule, any of the following opioids, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.

(1) Acetylmethadol;
(2) Allylprodine;
(3) Alphacetylmethadol;
(4) Alphameprodine;
(5) Alphamethadol;
(6) Alpha-methyl fentanyl;
(7) Benzethidine;
(8) Betacetylmethadol;
(9) Betameprodine;
(10) Betamethadol;
(11) Betaprodine;
(12) Clonitazene;
(13) Desmethyltramadol;
(14) Dextromoramide;
(15) Diampromide;
(16) Diethylthiambutene;
(17) Dimethylthiambutene;
(18) Difenoxin;
(19) Dimenoxadol;
(20) Dimepheptanol;
(21) Dimethylthiambutene;
(22) Dioxaphetyl Butyrate;
(23) Dipipanone;
(24) Ethylmethylthiambutene;
(25) Etonitazene;
(26) Etoxeridine;
(27) Furethidine;
(28) Hydroxypethidine;
(29) Isotonitazene;
[~~**(29)**~~] **(30)** Ketobemidone;
[~~**(30)**~~] **(31)** Levomoramide;
[~~**(31)**~~] **(32)** Levophenacylmorphan;
[~~**(32)**~~] **(33)** Morpheridine;
[~~**(33)**~~] **(34)** Noracymethadol;
[~~**(34)**~~] **(35)** Norlevorphanol;
[~~**(35)**~~] **(36)** Normethadone;
[~~**(36)**~~] **(37)** Norpipanone;
[~~**(37)**~~] **(38)** Phenadoxone;
[~~**(38)**~~] **(39)** Phenampromide;
[~~**(39)**~~] **(40)** Phenomorphan;
[~~**(40)**~~] **(41)** Phenoperidine;
[~~**(41)**~~] **(42)** Piritramide;
[~~**(42)**~~] **(43)** Proheptazine;
[~~**(43)**~~] **(44)** Properidine;
[~~**(44)**~~] **(45)** Propiram;

[~~(45)~~] **(46)** Racemoramide;

[~~(46)~~] **(47)** Tilidine;

[~~(47)~~] **(48)** Trimeperidine

[~~(48)~~] **(49)** U-48800; (2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide, monohydrochloride;

[~~(49)~~] **(50)** U-49900; (trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide;

[~~(50)~~] **(51)** Beta-Hydroxy-3-Methylfentanyl;

[~~(51)~~] **(52)** 3-Methylthiofentanyl;

[~~(52)~~] **(53)** Acetyl-Alpha-Methyl fentanyl ;

[~~(53)~~] **(54)** Alpha-Methylthiofentanyl ;

[~~(54)~~] **(55)** Beta-hydroxfentanyl ;

[~~(55)~~] **(56)** Para-Fluoro fentanyl;

[~~(56)~~] **(57)** Thiofentanyl;

[~~(57)~~] **(58)** Acetyl fentanyl;

[~~(58)~~] **(59)** Butyryl fentanyl;

[~~(59)~~] **(60)** Betahydroxythiofentanyl;

[~~(60)~~] **(61)** Furanyl fentanyl;

[~~(61)~~] **(62)** AH-7921; (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);

[~~(62)~~] **(63)** U47700; (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide);

[~~(63)~~] **(64)** MT-45; (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide);

[~~(64)~~] **(65)** W-15; (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide);

[~~(65)~~] **(66)** W-18; (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide);

[~~(66)~~] **(67)** U-50488; (2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide);

[~~(67)~~] **(68)** U50488H; ((-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclo-hexyl]benzeneacetamide).

[~~(68)~~] **(69)** Fentanyl-related substances, their isomers, esters, ethers, salts, and salts of isomers, esters and ethers. Fentanyl-related substance means any substance, unless specifically exempted or unless listed in another schedule, that is structurally related to fentanyl by one or more of the following modifications:

(a) replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;

(b) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups;

(c) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;

(d) replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or

(e) replacement of the N-propionyl group by another acyl group; or

(f) any combination of the above substances include, but are not limited to, the following substances:

(i) Acrylfentanyl;

(ii) 4F-butyrfentanyl;

(iii) 4-methoxybutyrfentanyl;

(iv) Fluorobutyrfentanyl;

(v) Fluorofentanyl;

(vi) FIBF; (Para Fluoro Isobutyryl Fentanyl);

(vii) Cyclopropyl fentanyl;

(viii) Thiofuranyl fentanyl (Thiophene fentanyl);

(ix) 3-methylfentanyl (N-3-methyl-1-(2-phenyl-ethyl)-4-Piperidyl)-N-phenylpropanamide, its optical and geometric isomers, salts and salts of isomers.

(x) crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);

(xi) valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide).

B. OPIUM DERIVATIVES: Unless specifically exempt or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation.

(1) Acetorphine;
(2) Acetyl dihydrocodeine;
(3) Benzyl morphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Dehydro morphine;
(9) Etorphine;
(10) Heroin;
(11) Hydromorphinol;
(12) Methyldesorphine;
(13) Methyldihydromorphine;
(14) Morphine methylbromide;
(15) Morphine methylsulfonate;
(16) Morphine-N-Oxide;
(17) Myrophine;
(18) Nicocodeine;
(19) Nicomorphine;
(20) Normorphine;
(21) Pholcodine;
(22) Thebacon;
(23) Drotebanol;
(24) 6AM; (6-acetylmorphine).

C. STIMULANTS: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.

(1) Fenethylline;
(2) N-ethylamphetamine;
(3) cis-4-methylaminorex;
(4) N, N-dimethylamphetamine;
(5) (BZP), 1-benzylpiperazine; N-benzylpiperazine;
(6) (DCPP); 2,3-dichlorophenylpiperazine;
(7) (DBZP); dibenzylpiperazine;
(8) (MBZP); methylbenzylpiperazine;
(9) (mCPP); meta-chlorophenylpiperazine;
(10) (MDBZP); methylenedioxybenzylpiperazine;
(11) (meOPP); para-methoxyphenylpiperazine;
(12) (pCPP); para-chlorophenylpiperazine;
(13) (pFPP); para-fluorophenylpiperazine;
(14) (2-DPMP), desoxypipradrol; 2-diphenylmethylpiperidine;
(15) D2PM, diphenylprolinol; diphenyl-2-pyrrolidinemethanol;
(16) HDMP-28; methylnaphthidate;
(17) Nocaine, (+)-CPCA; 3α-carbomethoxy-4β-(4-chlorophenyl)-N-methylpiperidine;
(18) BTQ or butyltolylquinuclidine; (2-Butyl-3-(p-tolyl)quinuclidine.

D. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Mecloqualone;
(2) Methaqualone;
(3) Benzodiazepines;
(a) Bromazepam;

(b) Camazepam;
(c) Cloxazolam;
(d) Delorazepam;
(e) Ethylloflazepate;
(f) Fudiazepam;
(g) Flunitrazepam;
(h) Haloxazolam;
(i) Ketazolam;
(j) Loprazolam;
(k) Lormetazepam;
(l) Medazepam;
(m) Nimetazepam;
(n) Nitrazepam;
(o) Nordiazepam;
(p) Oxazolam;
(q) Phenazepam
(r) Pinazepam;
(s) Tetrazepam;
(t) Flubromazepan;
(u) Diclazepam

(4) Gamma hydroxybutyric acid and any chemical compound that is metabolically converted to GHB;

(5) Gamma butyrolactone and any chemical compound that is metabolically converted to GHB;

(6) 1-4 butane diol and any chemical compound that is metabolically converted to GHB

(7) GHV or 4-methyl-GHB; γ-hydroxyvaleric acid;

(8) GVL; γ-valerolactone;

(9) MMQ; methylmethaqualone;

(10) MBQ; mebroqualone.

E. HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation (for purpose of this sub-section only, the term "isomers" includes the optical, positional, and geometric isomers).

(1) 3,4 -methylenedioxy amphetamine;

(2) 5 - methoxy - 3,4-methylenedioxy amphetamine;

(3) 3,4,5 -trimethoxy amphetamine;

(4) Bufotenine;

(5) DET; (Diethyltryptamine);

(6) DMT; (Dimethyltryptamine);

(7) DOM or STP; (4-methyl-2,5-dimethoxy amphetamine);

(8) Lysergic acid amide;

(9) Lysergic acid diethylamide;

[~~**(10)** Marijuana;~~]

[~~**(11)**~~] **(10)** Mescaline;

[~~**(12)**~~] **(11)** Peyote;

[~~**(13)**~~] **(12)** N-ethyl-3-piperidyl benzilate;

[~~**(14)**~~] **(13)** N-methyl-3-piperidyl benzilate;

[~~**(15)**~~] **(14)** Psilocybin;

[~~**(16)**~~] **(15)** Psilocyn;

[~~**(17)** Tetrahydrocannabinols;~~]

[~~**(18)**~~] **(16)** Parahexyl (synthetic analog of delta-9-tetrahydrocannabinol) [~~(THC) an active ingredient of cannabis)~~];

[~~**(19)** Hashish;~~]

[~~**(20)**~~] **(17)** 2, 5 -dimethoxyamphetamine; 2, 5-DMA;

[~~**(21)**~~] **(18)** 4-bromo-2, 5-dimethoxy-amphetamine; 2, 5-DMA;

[~~(22)~~] **(19)** PMA; 4-methoxyamphetamine;

[~~(23)~~] **(20)** PCE; (Ethylamine N-ethyl-1-phenylcyclohexylamine);

[~~(24)~~] **(21)** Pyrrolidine 1-(1-phenylcyclohexyl)-pyrrolidine (PCPy), (PHP) analog of the drug phencyclidine;

[~~(25)~~] **(22)** Thiophene (analog of phencyclidine) TCP or TPCP;

[~~(26)~~] **(23)** Alpha-ethyltryptamine;

[~~(27)~~] **(24)** 2, 5-dimethoxy-4-ethylamphet-amine;

[~~(28)~~] **(25)** Ibogaine;

[~~(29)~~] **(26)** 2C-T-7; (2,5-dimethoxy-4-(n)-propylthiophenethylamine);

[~~(30)~~] **(27)** AMT; (Alpha-methyltryptamine);

[~~(31)~~] **(28)** 5-MeO-DIPT; (5-methoxy-N,N-diisopropyltryptamine);

[~~(32)~~] **(29)** 25B-NBOMe; (2-(4-bromo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);

[~~(33)~~] **(30)** 25C-NBOMe; (2-(4-chloro-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);

[~~(34)~~] **(31)** 25I-NBOMe; (2-(4-iodo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine).

[~~(35)~~] **(32)** Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following synthetic cannabinoids which demonstrates binding activity to the cannabinoid receptor or analogs or homologs with binding activity. Substances include but are not limited to:

(a) CP 55,244 ((hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl] 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol);

(b) CP 55,940 (5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol);

(c) JWH-081 (1-pentyl-3-[1-(4-methoxynaphthoy)]indole);

(d) JWH-122 (1-pentyl-3-(4-methyl-1-naphthoyl)indole);

(e) JWH-133 3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H dibenzo[b,d]pyran;

(f) JWH 203 1-pentyl-3-(2-chlorophenylacetyl)indole);

(g) JWH 210 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone;

(h) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole);

(i) AM-1221 (1-(N-methylpiperdin-2-yl)methyl-2-methyl-3-(1-naphthoyl)-6-nitroindole;

(j) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);

(k) RCS-4 or SR-19 (1-pentyl-3-[(4-methoxy)-benzoyl]indole);

(l) RCS-8 or SR-18 (1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole);

(m) JWH-210 (1-pentyl-3-(4-ethylnaphthoyl)indole);

(n) WIN-49,098 (Pravadoline) (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone;

(o) WIN-55,212-2 (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-1,4-benzooxazin6- yl)-1-naphthalenylmethanone);

(p) any of the following synthetic cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation;

(i) naphthoylindoles: any compound containing a 3-(1- naphthoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398 and AM-2201;

(ii) naphthylmethylindoles: any compound containing a1Hindol- 3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-175, JWH-184, and JWH-199;

(iii) naphthoylpyrroles: any compound containing a 3-(1- naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-307;

(iv) naphthylmethylindenes: any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-176;

(v) phenylacetylindoles: any compound containing a 3- phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8;

(vi) cyclohexylphenols: any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with substitution at the 5- position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl ring to any extent including, but not limited to, Cannabicyclohexanol (CP 47,497 C8 homologue), CP 47,497 and CP 55,490;

(vii) benzoylindoles: any compound containing a 3-(benzoyl) [5] OTS-3833.4 indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4- morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241;

(q) UR-144 1-(pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;

(r) XLR11 1-(5-fluoro-pentyl)-1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone;

(s) AKB48 N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide;

(t) QUPIC; Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;

(u) 5-fluoro-PB22; 5F-PB22; Quinolin-8-yl 1-(5-fluropentyl-1H-indole-3-carboxylate;

(v) AB-FUBINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-flurobenzyl)-1H-indazole-3-carboxamide;

(w) ADB-PINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamine;

(x) AB-CHMINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;

(y) AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;

(z) THJ-2201; [1-(5-fluropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone;

(aa) FDU-PB-22 IUPAC: 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3 carboxylate;

(bb) 5-fluoro ABICA: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;

(cc) FUB-144 or FUB-UR-144; [1-(4-fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;

(dd) MN-18; N-(1-Naphthyl)-1-pentyl-1H-indazole-3-carboxamide;

(ee) FUB-PB-22; Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate;

(ff) ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);

(gg) AMB-FUBINACA or FUB-AMB **(**methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);

(hh) 5-fluoro-AMB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester);

(ii) 5-fluoro-ADB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine, methyl ester);

(jj) Bk-DMBDB or dibutylone; 1-(Benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-one;

(kk) MMB-FUBINACA; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate;

(ll) MDMB-CHMICA; methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;

(mm) NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;

(nn) 5-Fluoro-AKB48 or 5F-APINACA; N-((3s,5s,7s)-adamanta-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;

(oo) 5-Fluoro-ADB; Methyl(S)-2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate;

(pp) 5-Fluoro-AMB; N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine,methyl ester;

(qq) MAB-CHMINACA; N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cycohexylmethyl)-1H-indazole-3-carboxamide;

(rr) SDB-006; N-benxyl-1-pentyl-1H-indole-3-carboxamide;

(ss) Cumyl-PINACA; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide;

(tt) Cumyl-PICA; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide.

[~~**(36)**~~] **(33)** Substances determined by the board to have the pharmacological effect of the substance, the risk to the public health by abuse of the substance and the potential of the substance to produce psychic or physiological dependence liability is similar to the substances described in Paragraph (1) or (2) of 30-31-23C NMSA 1978. Substances include but are not limited to:

(a) Salvia divinorum;

(b) Salvinorin A (methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2*H*-benzo[f]isochromene-7-carboxylate);

[~~**(37)**~~] **(34)** (4-MEC); 4-methyl-ethylcathinone;

[~~**(38)**~~] **(35)** (4-EMC); 4-ethyl-methcathinone;

[~~**(39)**~~] **(36)** Ethcathinone; 2-ethylamino-1-phenyl-propan-1-one;

[~~**(40)**~~] **(37)** Ethylone; 3',4'-methylenedioxyethcathinone;

[~~**(41)**~~] **(38)** Bk-MBDB, butylone; beta-keto-N-methyl-3,4-benzodioxyolybutanamine;

[~~**(42)**~~] **(39)** (NRG-1), naphyrone; naphthylpyrovalerone;

[~~**(43)**~~] **(40)** Metamfepramone; N,N-dimethylcathinone;

[~~**(44)**~~] **(41)** Alpha-PPP; alpha-pyrrolidinopropiophenone;

[~~**(45)**~~] **(42)** (α-PBP); alpha-pyrrolidinobutiophenone;

[~~**(46)**~~] **(43)** (MOPPP); 4'-methoxy-alpha-pyrrolidinopropiophenone;

[~~**(47)**~~] **(44)** (MαPPP); 4'-methyl-α-pyrrolidinopropiophenone;

[~~**(48)**~~] **(45)** (MDPPP); 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone;

[~~**(49)**~~] **(46)** (MDPBP); 3',4'-methylenedioxy-alpha-pyrrolidinobutiophenone;

[~~**(50)**~~] **(47)** (MPBP); 4'-methyl-α-pyrrolidinobutiophenone;

[~~**(51)**~~] **(48)** Alpha-PVP; alpha-pyrrolidinovalerophenone;

[~~**(52)**~~] **(49)** (MDAI); 5,6-methylenedioxy-2-aminoindane;

[~~**(53)**~~] **(50)** Buphedrone; alpha-methylamino-butyrophenone;

[~~**(54)**~~] **(51)** Eutylone; beta-keto-ethylbenzodioxolylbutanamine;

[~~**(55)**~~] **(52)** beta-keto-ethylbenzodioxolylpentanamine;

[~~**(56)**~~] **(53)** beta-keto-methylbenzodioxolylpentanamine (pentylone);

[~~**(57)**~~] **(54)** 4-Bromo-2,5-dimethoxyphenethylamine (2c-B, Nexus);

[~~**(58)**~~] **(55)** N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alphamethyl-3,4(methylenedioxy)-phenethylamine, and N-hydroxy MDA;

[~~**(59)**~~] **(56)** 5-methoxy-N,N-dimethyltryptamine (5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT;

[~~**(60)**~~] **(57)** Mephedrone; 4-methylmethcathinone;

[~~**(61)**~~] **(58)** (MDPV); 3,4-methylenedioxypyrovalerone;

[~~**(62)**~~] **(59)** (2C-E); 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine;

[~~**(63)**~~] **(60)** (2C-D); 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine;

[~~**(64)**~~] **(61)** (2C-T-2); 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine;

[~~(65)~~] **(62)** (2C-T4); 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine;
[~~(66)~~] **(63)** (2C-H); 2-(2,5-Dimethoxyphenyl)ethanamine;
[~~(67)~~] **(64)** (2C-N); 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine;
[~~(68)~~] **(65)** (2C-P); 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine;
[~~(69)~~] **(66)** Methylone; 3,4-Methylenedioxy-N-methylcathinone;
[~~(70)~~] **(67)** Aminorex (2-amino-5-phenyl-2-oxazoline);
[~~(71)~~] **(68)** Pentedrone;
[~~(72)~~] **(69)** 4-FMC or flephedrone; 4-fluro-N-methylcathinone;
[~~(73)~~] **(70)** (3-FMC); 3-fluro-N-methylcathinone;
[~~(74)~~] **(71)** (3-MMC); 3-methylmethcathinone;
[~~(75)~~] **(72)** (3,4 DMMC); 3,4-Dimethylmethcathinone;
[~~(76)~~] **(73)** (3-MEC); 3-Methyl-N-ethylcathinone;
[~~(77)~~] **(74)** 4-methylbuphedrone or 4-MeBP; 2-methylamino-1-(4-methylphenyl)butan-1-one
[~~(78)~~] **(75)** (4 MTA); 4-methylthioamphetamine;
[~~(79)~~] **(76)** (5-Me MDA); 5-methyl-3,4-methylenedioxyamphetamine;
[~~(80)~~] **(77)** (6-APB); 6-benzofuran;
[~~(81)~~] **(78)** (PMA); 4-methoxyamphetamine;
[~~(82)~~] **(79)** (2C-B); 2,5-dimethoxy-4-bromophenethylamine;
[~~(83)~~] **(80)** (2C-C); 2,5-dimethoxy-4-chlorophenethylamine;
[~~(84)~~] **(81)** (2C-D); 4-methyl-2,5-dimethoxyphenethylamine;
[~~(85)~~] **(82)** (2C-E, aquarust, cindy); 2,5-dimethoxy-4-ethylphenethylamine;
[~~(86)~~] **(83)** (2C-G); 3,4-dimethyl-2,5-dimethoxyphenethylamine;
[~~(87)~~] **(84)** (2C-I); 2,5-dimethoxy-4-iodophenethylamine;
[~~(88)~~] **(85)** (2C-T21); 2-[2,5-dimethoxy-4-(2-fluoroethylthio)phenyl]ethanamine;
[~~(89)~~] **(86)** (2C-B-FLY); 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine;
[~~(90)~~] **(87)** Bromo-DragonFLY or 3C-Bromo-Dragonfly or DOB-Dragonfly; 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine;
[~~(91)~~] **(88)** (DOB); 2,5-Dimethoxy-4-bromoamphetamine;
[~~(92)~~] **(89** (DOC); 2,5-Dimethoxy-4-chloroamphetamine;
[~~(93)~~] **(90)** (DOM); 2,5-Dimethoxy-4-methylamphetamine;
[~~(94)~~] **(91)** (TMA2); 2,4,5-trimethoxyamphetamine;
[~~(95)~~] **(92)** (TMA6); 2,4,6-trimethoxyamphetamine;
[~~(96)~~] **(93)** (MDAT); 6,7-methylenedioxy-2-aminotetralin;
[~~(97)~~] **(94)** (4-acetoxy DiPT, ipracetin); 4-acetoxy-N,N-diisopropyltryptamine;
[~~(98)~~] **(95)** (4-acetoxy DMT, psilacetin;) O-Acetylpsilocin;
[~~(99)~~] **(96)** 4-HO MET, metocin; 4-hydroxy-N-methyl-N-ethyltryptamine;
[~~(100)~~] **(97)** 4-HO MiPT, hats; 4-hydroxy-N-methyl-N-isopropyltryptamine;
[~~(101)~~] **(98)** 5-MeO-aMT, Alpha-O; 5-methoxy-α-methyltryptamine;
[~~(102)~~] **(99)** (5-MeO-MiPT); N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine;
[~~(103)~~] **(100)** (DiPT); N,N-diisopropyltryptamine;
[~~(104)~~] **(101)** (DPT); dipropyltryptamine;
[~~(105)~~] **(102)** (5-MeO-DALT); N,N-diallyl-5-methoxytryptamine;
[~~(106)~~] **(103)** (3-MeO PCP); 3-methoxyphencyclidine;
[~~(107)~~] **(104)** (4-MeO PCP); 4-methoxyphencyclidine;
[~~(108)~~] **(105)** (MK-801); dizocilpine;
[~~(109)~~] **(106)** (PCE, perchloroethylene, perchloroethene), Perc; tetrachloroethylene;
[~~(110)~~] **(107)** (PCE, perchloroethylene, perchloroethene), Perc; tetrachloroethylene;
[~~(111)~~] **(108)** (PCPr); phencyclamine, N-(1-phenylcyclohexyl)propanamine;
[~~(112)~~] **(109)** (Tenocyclidine); 1-(1-(2-thienyl)cyclohexyl)piperidine
[~~(113)~~] **(110)** (3-MeO PCE); 3-methoxyeticyclidine, N-ethyl-1-(3-methoxyphenyl)cyclohexanamine;
[~~(114)~~] **(111)** (ETH-LAD); 6-ethyl-6-nor-lysergic acid diethylamide;
[~~(115)~~] **(112** (AL-LAD); 6-allyl-6-nor-LSD;

[~~**(116)**~~] **(113)** (PRO-LAD); 10-didehydroergoline-8-carboxamide.

F. Any material, compound, mixture or preparation which contains any quantity of the following substances.

(1) 3, 4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts and salts of isomers;

(2) (MPPP); 1-methyl-4-phenyl-4-proprionoxypiperidine its optical isomers, salts, and salts of isomers;

(3) 1-(-2-phenylethyl)-4-phenyl-4-acetoxy piperidine (PEPAP), its optical isomers, salts and salts of isomers;

(4) Cathinone;

(5) Methcathinone;

(6) Tianeptene.

[16.19.20.65 NMAC - Rp 16.19.20.65 NMAC, 6/26/2018; A, 12/17/2019; A, 9/14/2021]

16.19.20.68 SCHEDULE IV: Shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

A. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Alfaxalone;

(2) Alprazolam;

(3) Barbital;

(4) Chloral Betaine;

(5) Chloral Hydrate;

(6) Chlordiazepoxide;

(7) Clobazam;

(8) Clonazepam;

(9) Clorazepate;

(10) Clotiazepam

(11) Diazepam;

(12) Estazolam;

(13) Ethchlorvynol;

(14) Ethinamate;

(15) Flurazepam;

(16) Fospropofol;

(17) Halazepam;

(18) Lorazepam;

(19) Mebutamate;

(20) Meprobamate;

(21) Methohexital;

(22) Methylphenobarbital;

(23) Midazolam;

(24) Oxazepam;

(25) Paraldehyde;

(26) Petrichloral;

(27) Phenobarbital;

(28) Prazepam;

(29) Quazepam;

(30) Remimazolam;

[~~**(30)**~~] **(31)** Suvorexant;

[~~**(31)**~~] **(32)** Temazepam;

[~~**(32)**~~] **(33)** Triazolam.

B. FENFLURAMINE: Any material, compound, mixture or preparation which contains any quantity of the following substance, including its salts, isomers (whether optical, positional, or geometric) and its salts, or such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible: Fenfluramine.

C. LORCASERIN: Any material, compound, mixture or preparation which contains any quantity of the following substance, including its salts, isomers (whether optical, positional, or geometric) and its salts, or such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible: Lorcaserin.

D. STIMULANTS: Unless specifically exempt or unless listed in another schedule any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, positional, or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Diethylpropion;
(2) Phentermine;
(3) Pemoline (including organometallic complexes and chelates thereon);
(4) Pipradrol;
(5) SPA ((-)-1-dimethyl amino-1,2-diphenylmethane);
(6) Mazindol;
(7) Cathine;
(8) Fencamfamin;
(9) Fenproporex;
(10) Mefenorex;
(11) Modafinil;
(12) Sibutramine.

E. OTHER SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:

(1) Dextropropoxyphene(Alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane);
(2) Pentazocine;
(3) Carisoprodol;
(4) Nalbuphine Hydrochloride;
(5) Butorphanol Tartrate;
(6) Dezocine;
(7) Dichloralphenazone;
(8) Zaleplon;
(9) Zolpidem;
(10) Eszopiclone;
(11) Tramadol;
(12) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers.

F. NARCOTIC DRUG: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof: Not more than one milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

G. EXEMPTION OF CHLORAL: When packaged in a sealed, oxygen-free environment, under nitrogen pressure, safeguarded against exposure to the air. Chloral when existing under the above conditions is a substance which is not intended for general administration to a human being or another animal, and contains no narcotic controlled substances and is packaged in such a form that the package quantity does not present any significant potential for abuse. All persons who engage in industrial activities with respect to such chloral are subject to registration; but shall be exempt from Section 30-31-16 through 19 of the New Mexico Controlled Substances Act and 16.19.20.19 NMAC through 16.19.20.52 NMAC of the board of pharmacy regulations.

H. EXEMPT COMPOUNDS: Librax and Menrium are preparations which contain chlordiazepoxide, a depressant listed in schedule IV, Paragraph (6) of Subsection A of 16.19.20.68 NMAC and other ingredients in such combinations, quantity, preparation or concentration as to vitiate the potential for abuse of chlordiazepoxide, and are hereby exempt preparations.

(1) Librax;
(2) Menrium, 5-2;
(3) Menrium, 4-5;

(4) Menrium, 10-4.

[16.19.20.68 NMAC - Rp 16.19.20.68 NMAC, 6/26/2018; A, 9/14/2021]

16.19.20.69 SCHEDULE V:

A. Narcotic drugs containing non-narcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which shall include one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone.

(1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.

(2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.

(3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.

(4) Not more than two and five-tenths milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.

(5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.

(6) Not more than five-tenths milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

B. Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers.

(1) Pyrovalerone.

(2) Pseudoephedrine as a drug that includes any compound, mixture, or preparation that contains any detectable quantity of pseudoephedrine, its salts or its optical isomers, or salts of its optical isomers. Pursuant to 30-31-10.C the following substances are excluded from schedule V controlled substances: pseudoephedrine products in liquid form including liquid filled gel caps and pseudoephedrine products already classified as dangerous drugs.

C. Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:

(1) Lacosamide [(R)-2acetoamido-N-benzyl-3-methoxy-propionamide]

(2) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]

(3) Ezogabine [N-[2-amino-4-(4-flurobenzylamino-phenyl]-carbamic acid ethyl ester]

(4) Brivaracetam

(5) Cenobamate

[16.19.20.69 NMAC - Rp 16.19.20.69 NMAC, 6/26/2018; A, 12/17/2019, A, 12/15/2020; A, 9/14/2021]